Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solrikitug-Based Bispecific 1
- Development stage
- Preclinical
- Lead developer
- Uniquity Bio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Solrikitug-Based Bispecific 1 is a preclinical-stage bispecific antibody being developed by Uniquity Bio. It is engineered using the sequence of solrikitug, a high-affinity monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), which Uniquity in-licensed from Merck & Co. The bispecific molecule is designed to target TSLP along with a second, undisclosed target to simultaneously modulate multiple immune and inflammatory pathways. This approach is intended to provide enhanced therapeutic benefit over TSLP inhibition alone in the treatment of immune-mediated diseases, particularly in the respiratory and gastrointestinal fields.
- Other names
- Solrikitug-based bispecific 1-Uniquity-TSLP (Thymic Stromal Lymphopoietin)-undisclosed-bispecific antibody-undisclosed
02
Targets
TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on Solrikitug-Based Bispecific 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solrikitug-Based Bispecific 1.